Professor Trevor Hambley,Head of School and Director, Centre for Structural Biology and Structural Chemistry.
Brief CV:
Professor Hambley has studied and worked at the Universities of Western
Australia and Adelaide, ANU, The University of Sydney, Emory University
and Birkbeck College, University of London. He was the recipient of the
Edgeworth David Medal in 1989 for contributions to Science by an
Australian under the age of 35. He received the "Supervisor of the Year"
award at the University of Sydney in 1997 and an Excellence in Teaching
Award for Postgraduate Supervision in 1998.
Over the last 17 years Prof. Hambley has developed a reputation in the study of the mechanism of action of Pt based anticancer drugs and their interactions with biomolecules. He has been invited to present the results of this work at twelve major international meetings since 1999 including the 8 and 9th International Symposia on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy (ISPCC-8 and -9), the 9th International Conference on Bioinorganic Chemistry (ICBIC-99), the American Chemical Society meeting in San Francisco in March 2000, a conference celebrating the work of Mendel in Brno, Czech Republic in July 2000, the PacificChem conference in Hawaii in December 2000, ICBIC-2001 (Florence, August, 2001), Frontiers in Chemical Design and Synthesis (SICC2, Singapore, December 2001) and Eurobic 2004 (Germany, September, 2004). He was invited to chair the nucleic acids section at the inaugural Metals in Medicine Gordon Conference (Boston, July 2002).
Prof. Hambley has published 3 books, 12 reviews and more than 400 refereed journal papers, including four recent reviews of the relationship between the structure of Pt anticancer agents and their toxicity and anticancer activity and on the modelling of Pt/DNA interactions. He has had four recent invitations to produce book chapters, three to be published in 2003 and one in 2004. At the end of 2001, his publications had received 3205 citations excluding self-citations, an increase of 309 (10.7%) in the previous twelve months. Based on citations in 1981-1997, he ranks as the 528th most cited chemistry author worldwide which places him in the top 0.1%. He is a member of the Editorial Boards of the Journal of Inorganic Biochemistry and the Journal of Biological Inorganic Chemistry. He was the initiator and a Co-guest Editor of a special issue of this journal that arose from the 8th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy.
Brief summary of expertise and significant research achievements:
Professor Hambley (CI) has contributed to a number of areas including
molecular modelling, crystallography and medicinal inorganic chemistry.
His most recent contributions have been in the area of medicinal inorganic
chemistry and in particular Pt anticancer drugs.
Prof. Hambley was among the first to employ theoretical modelling to investigate Pt/DNA interactions and the first to show how these methods could be used to rationally design complexes to control their interactions with DNA. This led to the design of complexes that are as effective as cisplatin in interstrand cross-linking DNA, but are 50 fold less active, providing strong evidence that interstrand adducts are not primarily responsible for anticancer activity in these complexes. It has also led to the design of a series of chiral complexes that have greatly improved the understanding of the factors that control the binding of Pt to DNA. With Prof. Berners-Price, he was the first to obtain experimental confirmation that Pt/DNA adduct distributions are determined at the level of monofunctional adduct formation. Together, this work led to an invitation to write a Perspective for Dalton Transactions on the factors influencing platinum(II) binding to DNA.
More recently, Prof. Hambley has made major contributions to the understanding of the chemistry and biochemistry of platinum(IV) complexes. He was the first to investigate the relationship between the reduction potentials of Pt(IV) complexes and their biological activity, now a rapidly developing area. He has also developed independently, and with others, methods for controlling the solubility and lipophilicity of platinum(IV) complexes. This work has resulted in an association with IDT Australia aimed at taking a number of novel platinum(IV) complexes into the clinic.
Most recently, Prof. Hambey and his group have been the first to develop synchrotron radiation based methods for the in situ determination of oxidation states of platinum in biological environments and for reliably determining platinum distributions in these environments. Prof. Hambley has also investigated cobalt complexes as delivery agents for matrix metalloproteinase inhibitors and used XANES to determine oxidation states of the cobalt complexes in solution. This work is recognised as being world leading and has led to an invitation to use a new beam line at the Advanced Photon Source in Chicago and to be a speaker at the APS Biological Applications of Hard X-ray Microscopy Workshop.
International linkages:
Professor Peter Sadler (University of Edinburgh)
Professor Nick Farrell (Virginia Commonwealth University)
Dr Richard Callaghan (Oxford University).
Relevant grants:
| 2002-2004 | Design, Evaluation, and Selection of Novel Pt(IV) Complexes as Anticancer Agents. T. W. Hambley and G.B. Deacon, $301,510 |
| 2002-2004 | Design, Evaluation, and Selection of Novel Pt(IV) Complexes as Anticancer Agents, T. W. Hambley and G.B. Deacon, $150,000. |
| 2003-2005 | Development and Biological Chemistry of Novel Platinum Anti-Cancer Agents, T. W. Hambley and G.B. Deacon, $151,148. |
| 2004-2006 | Probing and Developing Hypoxia-Selective Anti-Cancer Agents, T. W. Hambley, $240,000. |
| 2004-2006 | Metal-Based Anti-inflammatory Drugs with High Efficacy and Low Side-Effects, P.A. LayS.G. PearceC.T. Dillon, $340,000. |
Relevant publications:
BOOKS
1. Molecular Modeling of Inorganic Compounds.
Second Edition, Completely Revised and Expanded
P. Comba and T.W. Hambley.
Wiley-VCH, Weinheim, Germany, 2001.
BOOK CHAPTERS
2. Copper and Zinc Complexes as Anti-Inflammatory Drugs.
C.T. Dillon, T.W. Hambley, B.J. Kennedy, P.A. Lay, J.E. Weder,
and Q. Zhou. Metal Ions and Their Complexes in Medication,
Volume 41 of Metal Ions in Biological. Systems, A. Sigel and
H. Sigel, editors., M. Dekker, New York, in press.
3. Platinum(IV) Anticancer Complexes. M. D. Hall, R. Dolman,
and T. W. Hambley. Metal Ions and Their Complexes in Medication
and in Tumor Diagnosis and as Anticancer Agents, Volume 42 of
Metal Ions in Biological. Systems, A. Sigel and H. Sigel, editors.,
M. Dekker, New York, in press.
4. Platinum. L. M. Rendina and T.W. Hambley
Comprehensive Coordination Chemistry, 2nd Edition,
in press.
INVITED REVIEWS
6. Molecular Mechanics Modelling of Pt/Nucleotide and Pt/DNA Interactions.
T.W. Hambley and A.R. Jones.
Coordination Chemistry Reviews, 2001, 212, 35-59.
7. Platinum Binding to DNA: Structural Controls and Consequences.
T.W. Hambley. Journal of the Chemical Society, Dalton Transactions,
2001, 2711-2718.
8. Platinum(IV) Antitumour Compounds: Their Bioinorganic Chemistry.
M.D. Hall and T.W. Hambley.
Coordination Chemistry Reviews, 2002, 232, 49-67.
9. Copper Complexes of Non-steroidal Anti-inflammatory Drugs: An
Opportunity Yet to be Realized. J.E. Weder, C.T. Dillon, T.W. Hambley,
B.J. Kennedy, P.A. Lay, J.R. Biffin, H.L. Regtop, N.M. Davies Coordination
Chemistry Reviews, 2002, 232, 95-126.
REFEREED JOURNAL PAPERS
309. Modification of Platinum(II) Antitumor Complexes with Sulfur
Ligands. Part I. Synthesis, Structure and Spectroscopic Properties of
Cationic Complexes of Type [PtCl(diamine)(L)]NO3 and
[{PtCl(diamine)}2(L-L](NO3)2 (L = Monofunctional Thiourea derivative;
L-L = Bifunctional Thiourea Derivative)
U. Bierbach, T.W. Hambley and N. Farrell.
Inorganic Chemistry, 1998, 37, 708-716.
317. The van der Waals Radii of Pt(II) and Pd(II) in Molecular Mechanics
Models and an Analysis of their Relevance to the Description of
Axial M ··· H(-C), M ··· H(?N), M ··· S and M ··· M (M = Pd(II) or
Pt(II)) Interactions.
T.W. Hambley.
Inorganic Chemistry, 1998, 37, 3767-3774.
319. The Dichloroplatinum(II) Complex of 5,5,7-trimethyl-1,4-diazacycloheptane:
Preparation, Crystal Structure and Binding to Nucleotides and DNA.
C.-L. Teo, R.R. Fenton, P. Turner and T.W. Hambley
Australian Journal of Chemistry, 1998, 51, 977-984.
325. Rates of Platination of AG and GA Containing Double Stranded
Oligonucleotides: Insights into why Cisplatin Binds to GG and AG but not
GA Sequences in DNA.
M.S. Davies, S.J. Berners-Price and T.W. Hambley.
Journal of the American Chemical Society, 1998, 120, 11380-11390.
326. [Pt2Cl2(m2-O2)2([9]aneN3)2]Cl2 : A Novel Platinum(IV) Dimer with Two
Bridging Peroxo Ligands that Provides Insight into the Mechanism of Aerial
Oxidation of Pt(II).
M.S. Davies and T.W. Hambley
Inorganic Chemistry, 1998, 37, 5408-5409.
329. The Resolution of 5,5,7-trimethyl-1,4-diazacycloheptane: Coordination
to Platinum(II), Crystal Structure of the Dichloroplatinum(II) Complex and
HPLC Separation of the [Pt(GpG)(tmdz)] Adducts.
V.P. Munk, R.R. Fenton and T.W. Hambley.
Polyhedron, 1999, 18, 1039-1043.
330. The Nature of Close Pd ··· Pd and Pd ··· H(¾C) contacts.
The Crystal Structures of R-Aminohexahydroazepinedichloropalladium(II),
and N?Ethyl-R-aminohexahydroazepinedichloropalladium(II) and a
Molecular Mechanics Analysis of the Close Contacts.
R.R. Fenton, F. Huq and T.W. Hambley.
Polyhedron, 1999, 18, 2149-2156.
331. Anti-Inflammatory Dinuclear Copper(II) Complexes with Indomethacin.
Synthesis, Magnetism and Epr Spectroscopy; Crystal Structure of the
N,N-Dimethylformamide Adduct.
J.E. Weder, T.W. Hambley, B.J. Kennedy, P.A. Lay, D. MacLachlan,
R. Bramley, C.D. Delfs, K.S. Murray, O. Moubarani, B. Warwick, J.R. Biffin
and H.L. Regtop
Inorganic Chemistry, 1999, 38, 1736-1744.
332. Three New Platinum(II)-Dipeptide Complexes.
D. Shi, T.W. Hambley and H.C. Freeman.
Journal of Inorganic Biochemistry, 1999, 73, 173-186.
335. Synthesis, Structure, Biological Activity, and DNA Binding of
Platinum(II) Complexes of the Type trans-[PtCl2(NH3)L] (L = Planar Nitrogen
Base). Effect of L and Cis/Trans Isomerism on Sequence Specificity and
Unwinding Properties Observed in Globally Platinated DNA.
U. Bierbach, Y. Qu, T.W. Hambley, J. Peroutka, H.L. Nguyen, M. Doedee
and N. Farrell.
Inorganic Chemistry, 1999, 38, 3535-3542.
338. Modifying the properties of platinum(IV) complexes in order to
increase biological effectiveness.
T.W. Hambley, A.R. Battle, G.B. Deacon, E.T. Lawrenz, G.D. Fallon,
B.M. Gatehouse, L.K. Webster and S. Rainone.
Journal of Inorganic Biochemistry, 1999, 77, 3-12.
341. Rates of Platination of -AG- and -GA- Containing Double Stranded
Oligonucleotides: Effect of Chloride Concentration.
M.S. Davies, S.J. Berners-Price and T.W. Hambley.
Journal of Inorganic Biochemistry, 2000, 79, 167-172.
343. Relationshsips between Hydrophobicity, Accumulation and
Peripheral Nerve Toxicity of a Series of Platinum Drugs.
D. Screnci, M.J. McKeage, P. Galettis, T.W. Hambley, B.D. Palmer
and B.C. Baguley.
British Journal of Cancer, 2000, 84, 966-972.
344. The preparation, characterization, and DNA adduct profile of
2-amino-2-methyl-3-butanoneoximedichloroplatinum(II), a platinum(II)
complex designed to bind to GpA sequences of DNA.
E.C.H. Ling, G.W. Allen, K. Vickery and T.W. Hambley.
Journal of Inorganic Biochemistry, 2000, 78, 55-62.
346. Syntheses and Characterization of Anti-inflammatory Dinuclear
and Mononuclear Zinc Indomethacin Complexes. Crystal Structures of
[Zn2(Indomethacin)4(L)2] (L = N,N-Dimethylacetamide,
Pyridine,1-Methyl-2-pyrrolidinone) and [Zn(Indomethacin)2(L1)2]
(L1 = Ethanol, Methanol).
Q. Zhou, T.W. Hambley, B.J. Kennedy, P.A. Lay, P. Turner, B. Warwick,
J.R. Biffin and H.L. Regtop.
Inorganic Chemistry, 2000, 39, 3742-3748.
347. Increased targeting of adenine rich sequences by 2-amino-2-methyl
-3-butanoneoximedichloroplatinum(II) and investigations into its low
cytotoxicity.
T.W. Hambley, E.C.H. Ling, S. O'Mara, M.J. McKeage and P.J. Russell.
Journal of Biological Inorganic Chemistry, 2000, 6, 675-681.
348. Studies on the Nature and Strength of Pt ··· H(-N) Interactions.
The Crystal structures of Chloro[N-(2-aminoethyl)-N-(2-ammonioethyl)ethane-
1,2-diamine]platinum(II) chloride and Dichloro[4,7-diaza-1-azoniacyclononane]
platinum(II) Tetrachloroplatinate(II) water(1/2) and a Molecular Mechanics
Analysis of the Pt ··· H(-N) Interactions.
M.S. Davies, R.R. Fenton, F. Huq, E.C.H. Ling and T.W. Hambley,
Australian Journal of Chemistry, 2000, 53, 451-456.
351. The Structure of a Methyl-Palladium(II) Complex of
2-Pyridinecarboxylato and Triphenylphosphine, [Pd(CH3)(N-O)(PPh3)].
T.W. Hambley, K.E. Frankcombe, B.F. Yates, K. J. Cavell and R.B. Knott.
Australian Journal of Chemistry, 2000, 53, 805-807.
352. Cisplatin Aquation is Slowed in the Presence of DNA but not by
Phosphate: An Improved Understanding of Sequence Selectivity and the
Roles of Monoaquated and Diaquated Species in the Binding of Cisplatin to DNA.
M.S. Davies, S.J. Berners-Price and T.W. Hambley.
Inorganic Chemistry, 2000, 39, 5603-5613.
354. Crystal structures of tris(hydroxamato) complexes of iron(III).
T.W. Failes and T.W. Hambley.
Australian Journal of Chemistry, 2000, 53, 879-881.
355. X-ray Crystallographic Structures of Biologically Active
Trishomocubanes of the Types Pentacyclo[5.4.0.02,6.03,10.05,9]undecylamines
and 4-Azahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodecane.
T.W. Hambley, R.B. Knott, M. Kassiou and M.J. Christie.
Australian Journal of Chemistry, 2000, 53, 899-904.
356. Determinations of the Structures of Anti-Inflammatory Copper(II)
Dimers of Indomethacin by Multiple Scattering Analysis of XAFS Data.
J.E. Weder, T.W. Hambley, B.J. Kennedy, P.A. Lay, G.J. Foran and
A.M. Rich.
Inorganic Chemistry, 2001, 40, 1295-1302.
357. Calculation of the Hydrophobicity of Platinum Drugs.
J.A. Platts, D.E. Hibbs, T.W. Hambley, and M.D. Hall.
Journal of Medicinal Chemistry, 2001, 44, 472-474.
358. Steric Control of Stereoselective Interactions between the
Diastereomeric Platinum(II) Complex, [PtCl2(1,4-diaza-cycloheptane)] and
DNA. Comparison with cis-[PtCl2(NH3)2] and [PtCl2(ethane-1,2-diamine)]
using DNA Binding and Molecular Modeling Studies.
T.W. Hambley, E.C.H. Ling, V.P. Munk and M.S. Davies.
Journal of Biological Inorganic Chemistry, 2001, 7, 534-542.
360. Structure, Stability and Interconversion Barriers of the Rotamers
of cis-[PtIICl2(quinoline)2] and cis-[PtIICl2(3-bromoquinoline)(quinoline)]
from X-ray Crystallography, NMR spectroscopy and Molecular Mechanics Evidence
M.S. Davies, C.I. Diakos, B.A. Messerle and T.W. Hambley.
Inorganic Chemistry, 2001, 40, 3048-3054.
361. Structure and Dynamics of a platinum(II) aminophosphine complex and
its nucleobase adducts.
A. Habtemariam, J.A. Parkinson, N. Margiotta, T.W. Hambley, S. Parsons and
P.J. Sadler.
Journal of the Chemical Society, Dalton Transactions, 2001, 362-372.
362. Trishomocubanes: Requirements for s Receptor Binding and Subtype
Selectivity.
X. Liu, M. Kassiou, M.J. Christie and T.W. Hambley
Australian Journal of Chemistry, 2001, 54, 31-36.
364. The Synthesis of Ethane-1,2-diamine-N,N'-bis(methylenephosphonic)
Acid and its Platinum(II) Complex, Bis{ethane-1,2-diamine-N,N'-bis
(methylenephosphonato)}platinum(II).
G. Giannikopoulos, J. Carter, R.R. Fenton and T.W. Hambley.
Australian Journal of Chemistry, 2001, 54, 127-130.
368. Preparation and Characterization of Dinuclear Copper-Indomethacin
Anti-Inflammatory Drugs.
Y.R. Morgan, P.Turner, B.J. Kennedy, T.W. Hambley, P.A. Lay, J.R. Biffin,
H.L. Regtop and B. Warwick.
Inorganica Chimica Acta, 2001, 324, 150-161.
369. Isomer formation in the binding of [PtCl2(cis-cyclohexane-1,3-diamine)]
to oligonucleotides and the X-ray crystal structure of [PtCl2(cis-cyclohexane-1,
3-diamine)].dimethylformamide.
S.T. Cham, C.I. Diakos, L.T. Ellis, R.R. Fenton, V.P. Munk, B.A. Messerle and
T.W. Hambley.
Journal of the Chemical Society, Dalton Transactions, 2001, 2769-2774.
370. Oxidation of [PtIICl2(ethane-1,2-diamine-N,N´-dicarboxylic acid)] and
Ligand Ring Closure in the Platinum(IV) Oxidation State.
P.N. Wong, M.S. Davies and T.W. Hambley.
Australian Journal of Chemistry, 2001, 54, 303-306.
372. Studies of the binding of a series of platinum(IV) complexes to
plasma proteins.
R.C. Dolman, G.B. Deacon and T.W. Hambley.
Journal of Inorganic Biochemistry, 2002, 88, 260-267.
373. Investigation of Palladium(II) and Platinum(II) Complexes With
Salicylhydroxamic Acid - Structural and Quantum Mechanical Studies.
M.D. Hall, T.W. Failes, D.E. Hibbs and T.W. Hambley.
Inorganic Chemistry, 2002, 41, 1223-1228.
374. Insights into Bonding and Hydrogen Bond Directionality in
Thioacetamide from the Experimental Charge Distribution.
T.W. Hambley, D.E. Hibbs, P. Turner, S.T. Howard and M.B. Hursthouse.
Journal of the Chemical Society, Perkin Transactions 1, 2002, 235-239.
375. Preparation and cell growth inhibitory activity of
[PtR2L2] (R = polyfluorophenyl, L2 = diene, cyclohexane-1,2-diamine (chxn)
or cis-(dimethyl sulfoxide)2) and the X-ray crystal structure of
[Pt(C6F5)2(cis-chxn)].
C. Cullinane, G.B. Deacon, P.R. Drago, T.W. Hambley, K.T. Nelson and
L.K. Webster.
Journal of Inorganic Biochemistry, 2002, 89, 293-301.
376. Examination of the Effects of Oxidation and Ring Closure on the
Cytotoxicities of the Platinum Complexes of N-(2-hydroxyethyl)ethane-
1,2-diamine and Ethane-1,2-diamine-N,N'-diacetic acid.
M.S. Davies, P.N. Wong and T.W. Hambley.
Journal of Inorganic Biochemistry, 2002, 91, 205-211.
377. A Statistical and Molecular Mechanics Analysis of the Effects
of Changing Donor Type on Bond-Length in the two Series [CoIIINnO6-n]
and [NiIINnO6-n] (n = 0 - 6): A New Route to Bond-Stretch Parameters.
R.K. Hocking and T.W. Hambley.
Inorganic Chemistry, 2002, 41, 2660-2666.
378. Minor Groove Intercalation of D-[Ru(Me2phen)2dppz]2+ to the
Hexanucleotide d(GTCGAC)2.
A. Greguric, I.D. Greguric, T.W. Hambley, J.R. Aldrich-Wright
and J.G. Collins.
Journal of the Chemical Society, Dalton Transactions, 2002, 849-855.
379. Cis-[PtCl2(NH3)(2-(2-hydroxyethyl)pyridine)] - an Analogue of the
Anticancer Drug ZD0473 : Unusual Hydrolysis Rates and pKa Values for the
Diaqua Adduct.
A.C.G. Hotze, Y. Chen, T.W. Hambley, S. Parsons, N.A. Kratochwil,
J.A. Parkinson, V.P. Munk and P.J. Sadler.
European Journal of Inorganic Chemistry, 2002, 1035-1039.
380. Synthesis, Spectroscopy, and Theoretical Studies of Platinum(II)
Phosphate Complexes.
A.R. Battle, J.A. Platts, T.W. Hambley and G.B. Deacon.
Journal of the Chemical Society, Dalton Transactions, 2002, 1898-1902.
382. Insights into the van der Waals Radius of Low-Spin Ni(II) from
Molecular Mechanics Studies and the Crystal Structures of
[Ni(cis-cyclohexane-1,3-diamine)2]Cl2, [Ni(R-5,5,7-trimethyl-1,4-
diazacycloheptane)2]Cl2.H2O and [Ni(5,7-dimethyl-1,4-diazacycloheptane)2]
(ClO4)2. Synthesis of 5,7-dimethyl-1,4-diazacycloheptane and an Improved
Synthesis of cis-Cyclohexane-1,3-diamine.
V.P. Munk, S.T. Cham, R.R. Fenton, R.K. Hocking, and T.W. Hambley
Australian Journal of Chemistry, 2002, 55, 523-529.
383. Electrochemistry, Protein Binding and Crystal Structures of
Platinum(II) and Platinum(IV) Carboxylato Complexes.
A.R. Battle, G.B. Deacon, R.C. Dolman and T.W. Hambley
Australian Journal of Chemistry, 2002, 55, 699-704.
387. Stereospecificity and Enantioselectivity in the Binding of the
Platinum(II) Complex [PtCl2(tmdz)] (tmdz = 5,5,7-trimethyl-1,4-
diazacycloheptane) to Dinucleotides and Oligonucleotides.
V.P. Munk, C.I Diakos, B.A. Messerle, R.R. Fenton, and T.W. Hambley
Chemistry, A European Journal, 2002, 8, 5486-5493.
389. Insights into Pt(II)-hydroxamate bonding through the crystal
structures of DMSO complexes.
T. W. Failes and T. W. Hambley.
Australian Journal of Chemistry, 2003, 56, 45-48.
391. Gastrointestinal Toxicity, Anti-Inflammatory Activity and Superoxide
Dismutase Activity of Copper and Zinc Complexes of the Anti-Inflammatory
Drug, Indomethacin.
C.T. Dillon, T.W. Hambley, B.J. Kennedy, P.A. Lay, Q. Zhou,
N.M. Davies, J.R. Biffin, and H.L. Regtop.
Chemical Research on Toxicology, 2003, 16, 28-37.
392. The Synthesis and In Vitro Cytotoxicity of trans-
dichlorodimethylsulfoxidetetrahydro-1,4-oxazineplatinum(II),
trans-[PtCl2(DMSO)(C4H9NO)] and trans-dichlorodimethylsulfoxide-5,
7-dimethyl-1,4-diazacyclohepteneplatinum(II), trans-[PtCl2(DMSO)(dmdze)].
G.Giannikopoulos, C.-L. Teo, M.D. Hall, R.R. Fenton and T. W. Hambley.
Australian Journal of Chemistry, 2003, 56, 685-689.
393. The first examples of platinum amine hydroxamate complexes:
structures and biological activity.
T.W. Failes, M.D. Hall, and T.W. Hambley
Dalton Transactions, 2003, in press.
394. Investigations into the interactions between DNA and conformationally
constrained pyridylamineplatinum(II) analogues of AMD473.
V.P. Munk, C.I. Diakos, L.T. Ellis, R.R. Fenton, B.A. Messerle and
T.W. Hambley.
Inorganic Chemistry, 2003, 43, 3582-3590.
395. A Structural Measure of Metal-Ligand Covalency from the Bonding in
Carboxylate Ligands.
R.K. Hocking and T.W. Hambley.
Inorganic Chemistry, 2003, 43, 3582-3583.
396. The interaction of metal ions and Marimastat with matrix
metalloproteinase 9.
C.K. Underwood, D. Min, J.G. Lyons and T.W. Hambley.
Journal of Inorganic Biochemistry, 2003, 95, 165-170.
398. The Cellular Distribution and Oxidation State of Platinum(II)
and Platinum(IV) Antitumour Complexes in Cancer Cells.
M.D. Hall, C.T. Dillon, M. Zhang, P. Beale, Z. Cai, B. Lai,
A.P.J. Stampfl, and T.W. Hambley.
Journal of Biological Inorganic Chemistry, 2003, 8, 726-732.
400. XANES Determination of the Platinum Oxidation State Distribution
in Cancer Cells Treated with Platinum(IV) Anticancer Agents
M.D. Hall, G.J. Foran, M. Zhang, P.J. Beale, and T.W. Hambley
Journal of the American Chemical Society, 2003, 125, 7524-7525.
402. The Preparation and Characterisation of Cyclam/Anthraquinone
Macrocyle/Intercalator Complexes and their Interactions with DNA.
L.T. Ellis, D.F. Perkins, P. Turner and T.W. Hambley
Dalton Transactions, 2003, 2728-2736.
405. XAFS Studies of Anti-inflammatory Dinuclear and Mononuclear
Zn(II) Complexes of Indomethacin
Q. Zhou, T.W. Hambley, B.J. Kennedy and P.A. Lay.
Inorganic Chemistry, 2003, in press.
406. Comparative efficacy of novel platinum(IV) compounds with
established chemotherapeutic drugs in solid tumour models.
M.D. Hall, C. Martin, D.J.P. Ferguson, R.M. Phillips, T.W. Hambley,
R. Callaghan.
Biochemical Pharmacology, 2003, in press.
